Effect of intravenous administration of FT-207 for gastric cancer
Otani, Y.; Yamanaka, T.; Kikuchi, H.; Namatame, K.; Yoshida, K.; Kataba, Y.; Maruyama, Y.; Watanabe, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(4): 857-860
1985
ISSN/ISBN: 0385-0684 PMID: 3920970 Document Number: 246448
FT-207, 800mg per day, was administered intravenously 2 hours per day for 6 days to 15 patients with gastric cancer. By chemical assay, FT-207 and 5-FU concentrations in the blood and tissues were determined. The FT-207 levels in cancerous tissue, metastatic lymph nodes and normal gastric mucosa were almost equal. The mean 5-FU level in cancerous lesions was 0.110 +/- 0.075mcg/g, and was 0.124 +/- 0.080mcg/g in lymph nodes, and 0.043 +/- 0.021mcg/g in normal mucosa. This showed that 5-FU levels were significantly higher in tumors and lymph nodes than in normal mucosa. (p less than 0.05, p less than 0.01 respectively). The mean blood level of 5-FU was low at 4 hours after FT-207 infusion. In conclusion, intravenous drip administration of FT-207 was considered to be effective for gastric cancer because of the high tumor affinity of 5-FU.